Reply
Honored Social Butterfly

Trump Announces Plasma Treatment Authorized for COVID-19

Trump Announces Plasma Treatment Authorized for COVID-19

 

NEWSMAX

 

President Donald Trump announced Sunday that the FDA has granted an emergency use authorization to use convalescent blood plasma from people who have recovered from COVID-19 to treat those who are newly diagnosed.

 

During a White House press conference Sunday evening, Trump — who was joined by FDA Commissioner Dr. Stephen Hahn and Health and Human Services Secretary Alex Azar — credited Operation Warpspeed for moving up the timeline to treat COVID-19 patients with new drugs and therapies.

 

The president added that the new treatment authorization is part of an overall effort that is "marshaling the full power and authority of the federal government" to help fight the pandemic.

Trump cited multiple studies and medical experts in saying the plasma treatment, which he called a "breakthrough," has been shown to lower the mortality rate of people who are sickened with the virus. Trump urged all Americans who have recovered from the virus to donate their blood plasma to help others fight the disease that has sickened nearly 6 million people in the U.S. More than 180,000 Americans have died since the pandemic started earlier this year.

 

Worldwide, 23.5 million people have gotten sick and more than 811,000 have died from the virus that originated in Wuhan, China. Trump referred to the virus several times during Sunday's briefing as the "China virus," a controversial term he's used in the past.

 

The blood plasma, taken from patients who have recovered from the coronavirus and rich in antibodies, may provide benefits to those battling with the disease. But the evidence has been inconclusive as to how it works or how best to administer it.
 

Many scientists and physicians believe that convalescent plasma might provide some benefit but it is far from a breakthrough. It is rich in antibodies that could be helpful in fighting the coronavirus, but the evidence so far has not been conclusive about whether it works, when to administer it and what dose is needed.

 

In a letter describing the emergency authorization, the chief scientist for the FDA, Denise Hinton, noted: "COVID-19 convalescent plasma should not be considered a new standard of care for the treatment of patients with COVID-19. Additional data will be forthcoming from other analyses and ongoing, well-controlled clinical trials in the coming months."

 

The White House had grown agitated with the pace of the plasma approval, but the accusations of a slowdown, which were presented without evidence, were just the latest assault from Trump’s team on the so-called “deep state” bureaucracy. White House chief of staff Mark Meadows did not deal in specifics, but said “we’ve looked at a number of people that are not being as diligent as they should be in terms of getting to the bottom of it.”

 

“This president is about cutting red tape,” said Meadows in an interview on ABC’s “This Week. “He had to make sure that they felt the heat. If they don’t see the light, they need to feel the heat because the American people are suffering.”

 

The push on Sunday came a day after Trump tweeted sharp criticism on the process to treat the virus, which has killed more than 175,000 Americans and imperiled his reelection chances. The White House has sunk vast resources into an expedited process to develop a vaccine and Trump aides have been banking on it being an “October surprise” that could help the president make up ground in the polls.

 

“The deep state, or whoever, over at the FDA is making it very difficult for drug companies to get people in order to test the vaccines and therapeutics,” Trump tweeted. “Obviously, they are hoping to delay the answer until after November 3rd. Must focus on speed, and saving lives!”

 

Earlier this month, Mayo Clinic researchers reported a strong hint that blood plasma from COVID-19 survivors helps other infected patients recover. But it wasn’t considered proof.

 

More than 64,000 patients in the U.S. have been given convalescent plasma, a century-old approach to fend off flu and measles before vaccines. It’s a go-to tactic when new diseases come along, and history suggests it works against some, but not all, infections.

 

There’s no solid evidence yet that it fights the coronavirus and, if so, how best to use it.

The Mayo Clinic reported preliminary data from 35,000 coronavirus patients treated with plasma, and said there were fewer deaths among people given plasma within three days of diagnosis, and also among those given plasma containing the highest levels of virus-fighting antibodies.

 

But it wasn’t a formal study. The patients were treated in different ways in hospitals around the country as part of an FDA program designed to speed access to the experimental therapy. That so-called “expanded access” program tracks what happens to the recipients, but it cannot prove the plasma — and not other care they received — was the real reason for improvement.

 

There’s been little data on how effective it is or whether it must be administered fairly early in an illness to make a significant difference, said Dr. William Schaffner, an infectious diseases expert at Vanderbilt University.

 

Rigorous studies underway around the country are designed to get that proof, by comparing similar patients randomly assigned to get plasma or a dummy infusion in addition to regular care. But those studies have been difficult to finish as the virus waxes and wanes in different cities. Also, some patients have requested plasma rather than agreeing to a study that might give them a placebo instead.

 

Meanwhile, former FDA commissioner Scott Gottlieb dismissed the suggestion of a slowdown.

“I firmly reject the idea they would slow-walk anything or accelerate anything based on any political consideration or any consideration other than what is best for the public health and a real sense of mission to patients,” Gottlieb told CBS's “Face the Nation.”

 

Hundreds of drugs are currently being developed as possible treatments against the coronavirus infection, taking a range of approaches.

 

Trump, in press conferences, “has made all kinds of therapeutic suggestions,” which have not proven to be supported by science — and are even dangerous, Schaffner said. That includes statements about the possible value of treating COVID-19 patients with ultraviolet light and bleach. Trump reportedly also recently became enthusiastic about oleandrin, a plant extract derived from a toxic shrub that scientists immediately warned against.

 

But the president is perhaps best known for his early and ardent embrace of the malaria drugs hydroxychloroquine and chloroquine.

 

The FDA in late March granted emergency authorization for distribution of the drugs for treating COVID. But in June, the agency revoked the authorization in light of growing evidence they don’t work and could cause serious side effects.

 

Not only that, the FDA warned doctors against prescribing the drugs in combination with remdesivir, a drug that was shown to help patients with COVID-19. The FDA said the anti-malaria drugs can reduce the effectiveness of remdesivir, which the FDA cleared for emergency use in May.

Earlier this month, Hahn emphasized that routine evaluation procedures will remain in place to evaluate COVID vaccine candidates.

 

A top FDA official who is overseeing COVID vaccine trials had vowed to resign if the Trump administration approves a vaccine before it is shown to be safe and effective. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, made his promise during a conference call earlier in the month with pharmaceutical executives, government officials and others, Reuters reported Friday.

 

“I think this administration has put more pressure on the Food and Drug Administration than I can remember” ever happening in the past, Schaffner said.

“Everybody is just a little bit nervous,” he said.

 
 
VIMTSTL
Esteemed Social Butterfly

Four days before the RNC the FDA wanted to slow down and get more information siding with scientists including Dr. Fauci.

 

T calls scientists, “deep state”

 

Tapes of his sister come out and suddenly it’s FDA approval for a treatment that was never blind tested, with perhaps a 35% efficacy rating.

 

https://www.statnews.com/2020/08/13/large-study-suggests-convalescent-plasma-can-help-treat-covid-19... 

 

As opposed to tested - like WHO states is showing promise.

 

Froze

And yes, after long days/nights, I'd still like to swing these hunks of glass , plastic and silicon against the nearest wall Come on retirement!
Honored Social Butterfly

This does look like a Trump product.  Insufficiently tested and overly hyped with a "what could it hurt" memo on the prescription bottle. 

Honored Social Butterfly

Dr. Nicole Saphier: Plasma therapy a promising step in fight against coronavirus

 

BY:  Dr. Nicole Saphier

 

For the last six months, the world has been fighting a novel pathogen with minimal treatment options and without a vaccine.

 

On Sunday, President Trump announced the Food and Drug Administration is issuing an emergency use authorization for (EUA) convalescent plasma in hospitalized patients, another step forward in the fight against COVID-19.

 

Plasma is the portion of blood that contains the important antibodies which block the spike protein of SARS-CoV-2 and ultimately prevent cellular replication and invasion of the virus into human tissues. The plasma is retrieved from people who have already recovered from COVID-19 and have circulating IgG antibodies in their bloodstream.

 

GOV. ASA HUTCHINSON: TO FIGHT CORONAVIRUS WEAR A MASK — NEW SURVEY SHOWS MOST AMERICANS AGREE

 

The use of convalescent plasma is not novel to scientific discovery. In fact, it’s been used for nearly a century treating various conditions. It has proven safe in a large reputable observational study performed by the Mayo Clinic in the treatment of COVID-19. The people in the study who benefited the most from the treatment were those over 80 years old not on a ventilator, the most vulnerable.

 

It may not be the magic ticket to end the pandemic, but can it save lives if sufficient quantities of IgG are given early enough? Data from over 30,000 people in the study suggest so. And because of that, every American should be rejoicing.

 

While there may be some people attempting to dampen the enthusiasm of the announcement, any treatment that is proving safe and potentially efficacious after being administered in over 70,000 Americans deserves praise. Convalescent plasma is currently being used across the country under an expanded access program but the EUA gives further access by cutting through potential administrative delays.

 

Since convalescent plasma treatment involves giving donated plasma with antibodies from patients who have recovered from COVID-19, it is imperative that people who have recovered from the illness donate to help others. Otherwise, there is a high likelihood that we will have a shortage of the treatment and many people will no be able to benefit from it.

 

In a similar vein, as we move forward exploring antibody therapy, monoclonal (lab manufactured) antibodies (mAbs) are declaring their role in treating COVID-19. Specifically, Leronlimab, created by a lesser-known biotech company CytoDyn, is currently enrolling two placebo-controlled double-blind clinical trials that have already entered Phase 3. Phase 2 results reported in July passed all safety checks.

 

Originally manufactured as an investigational injectable for HIV, Leronlimab is also demonstrating an ability to prevent and/or lessen the cytokine storm that causes much of the severity in COVID-19 symptoms. Albeit a small sample size, early Phase 1 results showed patients on Leronlimab experienced 63% less seriously adverse events than the control group, while also demonstrating reduction in viral load to zero after 14 days.

 

While all of this is promising, Phase 2 efficacy data has not been released yet. If that data demonstrate similar results to Phase 1, an EUA may be in the near future for this medication while Phase 3 enrollment is ongoing.

 

As children head back to school and outbreaks are still occurring, it is hopeful that we are making progress on the treatment front and the FDA is doing what it can to expedients safe treatments. For the over 1 million Americans who have already recovered from COVID-19, please consider donating your plasma today so that this potentially life-saving treatment can be readily available nationwide.

 

 

 

 

VIMTSTL
Honored Social Butterfly


@jimc91 wrote:

Dr. Nicole Saphier: Plasma therapy a promising step in fight against coronavirus

 

BY:  Dr. Nicole Saphier

 

For the last six months, the world has been fighting a novel pathogen with minimal treatment options and without a vaccine.

 

On Sunday, President Trump announced the Food and Drug Administration is issuing an emergency use authorization for (EUA) convalescent plasma in hospitalized patients, another step forward in the fight against COVID-19.

 

Plasma is the portion of blood that contains the important antibodies which block the spike protein of SARS-CoV-2 and ultimately prevent cellular replication and invasion of the virus into human tissues. The plasma is retrieved from people who have already recovered from COVID-19 and have circulating IgG antibodies in their bloodstream.

 

GOV. ASA HUTCHINSON: TO FIGHT CORONAVIRUS WEAR A MASK — NEW SURVEY SHOWS MOST AMERICANS AGREE

 

The use of convalescent plasma is not novel to scientific discovery. In fact, it’s been used for nearly a century treating various conditions. It has proven safe in a large reputable observational study performed by the Mayo Clinic in the treatment of COVID-19. The people in the study who benefited the most from the treatment were those over 80 years old not on a ventilator, the most vulnerable.

 

It may not be the magic ticket to end the pandemic, but can it save lives if sufficient quantities of IgG are given early enough? Data from over 30,000 people in the study suggest so. And because of that, every American should be rejoicing.

 

While there may be some people attempting to dampen the enthusiasm of the announcement, any treatment that is proving safe and potentially efficacious after being administered in over 70,000 Americans deserves praise. Convalescent plasma is currently being used across the country under an expanded access program but the EUA gives further access by cutting through potential administrative delays.

 

Since convalescent plasma treatment involves giving donated plasma with antibodies from patients who have recovered from COVID-19, it is imperative that people who have recovered from the illness donate to help others. Otherwise, there is a high likelihood that we will have a shortage of the treatment and many people will no be able to benefit from it.

 

In a similar vein, as we move forward exploring antibody therapy, monoclonal (lab manufactured) antibodies (mAbs) are declaring their role in treating COVID-19. Specifically, Leronlimab, created by a lesser-known biotech company CytoDyn, is currently enrolling two placebo-controlled double-blind clinical trials that have already entered Phase 3. Phase 2 results reported in July passed all safety checks.

 

Originally manufactured as an investigational injectable for HIV, Leronlimab is also demonstrating an ability to prevent and/or lessen the cytokine storm that causes much of the severity in COVID-19 symptoms. Albeit a small sample size, early Phase 1 results showed patients on Leronlimab experienced 63% less seriously adverse events than the control group, while also demonstrating reduction in viral load to zero after 14 days.

 

While all of this is promising, Phase 2 efficacy data has not been released yet. If that data demonstrate similar results to Phase 1, an EUA may be in the near future for this medication while Phase 3 enrollment is ongoing.

 

As children head back to school and outbreaks are still occurring, it is hopeful that we are making progress on the treatment front and the FDA is doing what it can to expedients safe treatments. For the over 1 million Americans who have already recovered from COVID-19, please consider donating your plasma today so that this potentially life-saving treatment can be readily available nationwide.

 

 

 

 


The article you use as support covers the Plasma Treatment for the the virus but does not cover in any way shape or form the problem Trump has caused by playing politics with it.

There is not sold proof what effect the plasma treatment is, and how its final use should be handled. The reason for that is there were no blind test groups. Part get drug, part do not and you see what the difference is in the 2 groups. Your support article covers this on testing of another drug for the virus.

What will happen now is there will be a good chance no phase 3 trial on any drug for the virus will go forwarded since all can get the plasma and not risk being in the do not get group. As your support article tells you all drugs have a 3 part test cycle to make sure they are safe, and how to use them, and that is what the medical experts were doing. Yes you can shorten the time and still have a 3 part cycle.

Trump only did this because he wanted to use it on TV this evening as he think it makes him look good. Trump is only for Trump just ask his sister.

Honored Social Butterfly

I am not a scientist so I don't understand the ramifications of this announcement. However, I do understand the level of political pressure Trump places on federal employees. Therefore, I am not surprised the FDA did something like this.

 

"Some scientists are concerned that the treatment has not been proved effective in randomized trials, but the Trump administration pushed for approval."

 

Let's hope this is an effective treatment. But if it turns out it is not effective, we know the FDA succumbed to political pressure from Trump.

cancel
Showing results for 
Show  only  | Search instead for 
Did you mean: 
Users
Announcements

Does AARP donate to political parties or endorse candidates?

AARP is strictly non-partisan and always has been. We never endorse or donate to candidates, political parties or political action committees.

Learn more.

AARP Members Only Games

Play members only games, like FIll Ins, Lumeno, 2048 and a collaborative, multiplayer Let's Crossword.

Play Now
AARP Members Only Games Logos
AARP Rewards

Solve Crosswords. Earn Rewards. Activate AARP Rewards to earn points for games, quizzes and videos. Redeem for deals and discounts.

Get started with AARP Rewards now!
/html/assets/Rewards-program-badge-355x224.png